- Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3.
- 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients alive as of data cutoff with median follow-up of 31 and 19 weeks, respectively.
- Promising clinical activity in R/R NPM1-m and KMT2A-r AML with ven/aza, including ven-experienced patients.
- Ziftomenib generally well tolerated in combination with standards of care at all dose levels studied
Kura Oncology Provided Clinical Data From KOMET-007 Phase 1 Dose-escalation Trial Of Ziftomenib In Combination With Standards Of Care For NPM1-mutant And KMT2A-rearranged Acute Myeloid Leukemia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated